Key Points
Rating and Frame We rate DarioHealth Buy with a new $12 twelve-month target. The July financing extends the implementation window and reduces liquidity pressure. The investment case centers on converting approximately $12.9 million of contracted and late-stage annual recurring revenue into recognized B2B2C sales. High recurring margins can create operating leverage, while covered-life access, unsigned negotiations, and eligible populations offer revenue potential as programs activate. Second-half operating progress would support the outlook, while further material equity issuance would weaken per-share value. Commercial continuity will also matter during the leadership transition.
Investment Case First-quarter revenue was $5.584 million, including $2.716 million of B2B2C revenue and $2.868 million of consumer revenue. B2B2C declined 42.7% year over year, adjusted consolidated gross margin was 60.6%, and operating cash use was $6.025 million. We estimate $25 million of 2026 revenue and $33 million in 2027. The thesis assumes B2B2C growth resumes, its approximately 80% company-defined non-GAAP margin holds, and recurring revenue becomes the primary source of gross profit. Consumer growth provides validation, while its lower-margin hardware economics offer less valuation support.
Operations Our milestones include third-quarter B2B2C revenue above $3 million with at least 10% sequential growth, followed by a fourth-quarter increase. We look for the Fortune 50 cardiometabolic program covering more than 100,000 eligible employees to launch during fall 2026 and begin contributing revenue by year-end. An executed channel partnership with a deployment schedule would add visibility. At least one Aetna or Centene extension would strengthen the recurring base and validate payer retention. Recognized revenue, enrolled members, and billable participation would provide the clearest evidence of progress.
Financials and Funding The registered direct offering generated estimated net proceeds of $22.828 million and added 3.469 million common equivalents. Including legacy pre-funded warrants, the minimum economic denominator is 13.188 million shares. Mechanical pro forma cash and deposits were $42.940 million before post-March operating use, compared with $32.5 million of debt principal and a $10 million liquidity covenant. Quarterly operating cash use is expected to trend below $5 million by year-end, while cash and deposits should remain above approximately $25 million. Share-count discipline is a central operating milestone and valuation assumption.
Capitalization, Valuation, and Risk The target represents $158 million of equity value on the financing-adjusted denominator. Our framework weights strong conversion, base conversion, and slippage at 45%, 45%, and 10%. Enterprise value is $156 million before modeled net cash. Strong and base cases use 5.25 and 4.20 times revenue. The valuation excludes a strategic transaction, care-delivery revenue, and full pipeline conversion. Material ATM use, extended implementations, weaker payer retention, or consumer-led mix would moderate the multiple and per-share value and are risks to our price target. This premium would gain support as recurring revenue scales faster than operating expense and financing risk declines.
Summary
Our Buy rating and $12 target are supported by sequential B2B2C growth, timely Fortune 50 activation, execution of the channel agreement, at least one payer extension, and adjusted consolidated gross margin improving toward the mid-60% range. Liquidity would ideally remain above the covenant floor with limited ATM use. Visible commercial conversion and improving cash use through the third-quarter report would strengthen the base case and support confidence in the rating and target
Rating, Price and Target
Symbol DRIO
Rating Buy
Price $7.79
Price Target (Prev.) $12.00 ($25.00)
Market Data
Market Cap (M) $54.1
Shares Outstanding (M) 9.8
Average Daily Volume (000s) 22.5
Float (M) 5.2
Total Debt (M) $32.5
Net Cash/Debt ($M) $2.0
Dividend NM
General: Pro forma debt and net cash: Total debt principal was $32.5 million. Estimated post-offering cash was approximately $34.5 million after intervening operating burn, implying approximately $2.0 million of net cash. July cash was not reported, so cash and net cash are analyst estimates.
FYE Dec 2024A 2025A
EPS1 (12.27)↑ (10.12)
Previous (21.04) (10.12)
Revenue (M) ($) 27.0 22.4↑
Previous 27.0 22.3
1Fully diluted shares outstanding: Approximately 14.1 million as of July 24, 2026, including 9.793 million pro forma common shares, 3.395 million pre-funded warrants, and approximately 0.92 million other warrants and options. The valuation denominator excludes high-strike securities and uses 13.188 million economic shares.
Company Description
DarioHealth Corp. (Nasdaq: DRIO) is a digital health company providing integrated chroniccondition management solutions to employers, health plans, providers, and consumers. Its platform combines connected medical devices, software, personalized coaching, behavioral support, and datadriven engagement across diabetes, hypertension, weight management, musculoskeletal care, and behavioral health. Dario primarily commercializes its services through business-to-business-to-consumer contracts and channel partnerships while also selling consumer products. The company is expanding toward provider-backed care and outcomes-based reimbursement. Investment performance depends on converting contracted programs into enrolled members, recurring revenue, higher-margin service mix, and lower cash burn while managing debt, customer concentration, and dilution risk carefully.
